Exponent
EXPO
68.95
-0.23
-0.33%
Exponent
US · EXPO
#2429 by market cap
Listed 1970
68.95
-0.23
-0.33%
Live - 5344 symbols - heartbeat 543s ago
· 2026-10-08 07:22
Pre-market
69.20
+0.36%
After-hours
68.95
0.00%
- Market cap
- 3.28B
- P/E (TTM)i
- 30.92
- P/Bi
- 11.36
- EPSi
- 2.07
- Div yieldi
- 1.77%
- 52W posi
- 60%
Reader sentiment
Are you bullish or bearish on EXPO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.93, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +4.21% YoY
Margins
- Operating margin
- 20.58%
- Net margin
- 18.21%
Key ratios & quality
- PEG ratioi
- 26.11
- Altman Z-Scorei
- 7.93
PEG uses trailing P/E against the 3-year net income growth rate (1.18%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 379.52M | 417.20M | 399.90M | 466.27M | 513.29M | 536.77M | 558.51M | 582.01M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 232.58M | 272.72M | 262.93M | 293.33M | 287.90M | 344.33M | 352.74M | 367.52M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 91.46M | 85.11M | 83.25M | 108.93M | 140.84M | 111.32M | 119.56M | 119.79M |
| Pretax profit | 93.32M | 104.19M | 96.94M | 125.84M | 132.23M | 135.90M | 147.37M | 147.30M |
| Tax | 21.06M | 21.73M | 14.38M | 24.64M | 29.90M | 35.56M | 38.37M | 41.29M |
| Net profit | 72.25M | 82.46M | 82.55M | 101.20M | 102.33M | 100.34M | 109.00M | 106.01M |
| Basic EPS | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Diluted EPS | 1.33 | 1.53 | 1.55 | 1.90 | 1.96 | 1.94 | 2.11 | 2.07 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 145.51M | 141.96M | 147.12M | 147.43M | 166.30M | 171.61M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 80.91M | 103.62M | 95.38M | 87.61M | 97.61M | 107.97M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 44.43M | 17.18M | 29.04M | 29.14M | 41.38M | 28.02M |
| Pretax profit | 37.76M | 36.82M | 38.62M | 34.11M | 42.34M | 40.77M |
| Tax | 11.11M | 10.26M | 10.57M | 9.34M | 12.77M | 11.37M |
| Net profit | 26.65M | 26.55M | 28.04M | 24.76M | 29.57M | 29.40M |
| Basic EPS | 1 | 1 | 1 | 0 | 1 | 1 |
| Diluted EPS | 0.52 | 0.52 | 0.55 | 0.49 | 0.59 | 0.60 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 326.61M | 364.04M | 366.83M | 452.76M | 349.16M | 379.53M | 446.88M | 427.58M |
| Cash & ST investments | 208.55M | 231.60M | 242.53M | 297.69M | 161.46M | 187.15M | 258.90M | 221.93M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 468.94M | 563.41M | 580.10M | 683.74M | 586.66M | 646.78M | 777.27M | 777.52M |
| Total current liabilities | 98.30M | 123.96M | 117.31M | 152.98M | 159.03M | 161.91M | 163.18M | 178.00M |
| Short-term debt | -- | 5.94M | 5.99M | 5.16M | 5.26M | 6.30M | 5.39M | 6.89M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 155,027,000.00 | 213,160,000.00 | 218,598,000.00 | 266,674,000.00 | 265,910,000.00 | 290,692,000.00 | 356,202,000.00 | 387,178,000.00 |
| Total equity | 313.91M | 350.25M | 361.50M | 417.07M | 320.75M | 356.09M | 421.07M | 390.34M |
| Retained earnings | 342.02M | 384.67M | 421.81M | 478.37M | 528.81M | 574.08M | 624.15M | 668.42M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 432.80M | 425.65M | 416.79M | 427.58M | 340.89M | 312.01M |
| Cash & ST investments | 245.11M | 231.80M | 207.38M | 221.93M | 118.55M | 66.63M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 763.24M | 759.43M | 761.45M | 777.52M | 687.38M | 652.72M |
| Total current liabilities | 130.27M | 134.97M | 154.77M | 178.00M | 142.20M | 157.84M |
| Short-term debt | 5.63M | 5.85M | 6.49M | 6.89M | 6.72M | 6.76M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 321,831,000.00 | 331,654,000.00 | 358,588,000.00 | 387,178,000.00 | 349,044,000.00 | 364,107,000.00 |
| Total equity | 441.41M | 427.78M | 402.86M | 390.34M | 338.34M | 288.62M |
| Retained earnings | 635.02M | 646.04M | 658.79M | 668.42M | 682.01M | 696.41M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 91.19M | 108.06M | 103.31M | 124.57M | 93.81M | 127.35M | 144.54M | 131.73M |
| Depreciation & amortization | 6.29M | 6.81M | 6.87M | 6.49M | 7.08M | 8.92M | 9.69M | 10.08M |
| Free cash flow | 74.89M | 85.02M | 98.33M | 117.74M | 81.76M | 111.00M | 137.60M | 122.34M |
| Dividends paid | -27.22M | -33.50M | -39.78M | -43.20M | -49.24M | -54.04M | -58.21M | -61.54M |
| Stock buybacks / issuance | -27.92M | -21.96M | -40.05M | -7.00M | -155.86M | -24.21M | -5.71M | -97.10M |
| Ending cash balance | 127.06M | 176.44M | 197.53M | 297.69M | 161.46M | 187.15M | 258.90M | 221.93M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | 7.27M | 36.22M | 32.65M | 55.58M | -975.00K | 30.89M |
| Depreciation & amortization | 2.49M | 2.52M | 2.53M | 2.54M | 2.52M | 2.68M |
| Free cash flow | 5.52M | 33.95M | 29.98M | 52.90M | -3.43M | 29.11M |
| Dividends paid | -16.37M | -15.22M | -15.07M | -14.89M | -16.58M | -14.76M |
| Stock buybacks / issuance | 0 | -32.68M | -40.03M | -24.38M | -78.76M | -67.38M |
| Ending cash balance | 245.11M | 231.80M | 207.38M | 221.93M | 118.55M | 66.63M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 23.97 | 24.83 | 23.20 | 26.00 | 27.74 | 29.65 | 28.05 | 26.13 |
| ROA %i | 15.91 | 15.98 | 14.44 | 16.02 | 16.11 | 16.27 | 15.31 | 13.64 |
| ROIC %i | 23.26 | 22.28 | 21.45 | 24.86 | 26.11 | 26.27 | 22.91 | 20.36 |
| 5-year avg ROE %i | 18.11 | 19.68 | 20.88 | 22.54 | 25.15 | 26.28 | 26.93 | 27.51 |
| EBIT margin %i | 24.10 | 20.40 | 20.82 | 23.36 | 27.44 | 20.74 | 21.41 | 20.58 |
| FCF / sales %i | 19.73 | 20.38 | 24.59 | 25.25 | 15.93 | 20.68 | 24.64 | 21.02 |
| Current ratioi | 3.32 | 2.94 | 3.13 | 2.96 | 2.20 | 2.34 | 2.74 | 2.40 |
| Quick ratioi | 3.20 | 2.84 | 3.02 | 2.86 | 2.08 | 2.19 | 2.58 | 2.27 |
| Debt / assetsi | 0.00 | 4.28 | 3.50 | 2.19 | 3.17 | 4.37 | 10.48 | 10.65 |
| LT debt / equityi | -- | 5.18 | 3.97 | 2.35 | 4.16 | 6.17 | 18.07 | 19.46 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 6.65 | 9.81 | 4.76 | 7.10 | 7.15 | 10.31 | 6.20 | 4.28 |
| Net income CAGR (3Y) %i | 18.34 | 20.20 | 25.96 | 11.89 | 7.46 | 6.72 | 2.51 | 1.18 |
| FCF CAGR (3Y) %i | 10.76 | 17.39 | 15.93 | 16.28 | -1.29 | 4.12 | 5.33 | 14.38 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | 25.87 | 25.05 | 25.79 | 26.13 | 27.94 | 31.20 |
| ROA %i | 15.15 | 14.00 | 13.93 | 13.64 | 15.02 | 15.83 |
| ROIC %i | 21.27 | 19.55 | 19.99 | 20.36 | 21.89 | 24.38 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 23.84 | 20.47 | 20.64 | 20.58 | 19.37 | 20.17 |
| FCF / sales %i | 24.00 | 21.57 | 21.51 | 21.02 | 18.81 | 17.16 |
| Current ratioi | 3.32 | 3.15 | 2.69 | 2.40 | 2.40 | 1.98 |
| Quick ratioi | 3.16 | 2.98 | 2.52 | 2.27 | 2.22 | 1.81 |
| Debt / assetsi | 10.50 | 10.58 | 10.85 | 10.65 | 11.79 | 12.37 |
| LT debt / equityi | 16.88 | 17.41 | 18.89 | 19.46 | 21.97 | 25.63 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Engineering and other scientific is the largest reported line at 86.72% of revenue, across 2 reported segments.
- The next-largest line, Environmental And Health, is a distant second at 13.28% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Engineering and other scientific86.72%
Environmental And Health13.28%
Quote time 2026-10-08 07:22:02 · For reference only, not investment advice and not tailored to your situation.